Belsomra

Chemical Namesuvorexant
Dosage FormTablet (oral; 5mg, 10mg, 20mg)
Drug ClassReceptor antagonists
SystemEndocrine
CompanyMerck & Co.
Approval Year2014

Indication

  • For the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Last updated on 6/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Belsomra (suvorexant) Prescribing Information2014Merck & Co., Whitehouse Station, NJ